EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One®…
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companiesSEATTLE and…
-- Six out of ten patients experienced complete responses in treated tumors with an additional two patients demonstrating partial responses…
The ELCAP guidance sets standards for responsible AI use in oncology, protecting patients and supporting clinicians LUGANO, Switzerland and BERLIN,…
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the…
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025…
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with…
Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study…